OTC Markets Group Welcomes RestorGenex to OTCQX

Jul 08, 2015, 07:00 ET from OTC Markets Group Inc.

NEW YORK, July 8, 2015 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced RestorGenex Corporation (OTCQX: RESX), a specialty biopharmaceutical company, has qualified to trade on the OTCQX® Best Marketplace.

Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO

RestorGenex begins trading today on OTCQX under the symbol "RESX."  U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

"RestorGenex is developing innovative biopharmaceutical therapies for the treatment of eye and skin diseases and cancer, specifically, brain cancer," said R. Cromwell Coulson, President and CEO of OTC Markets Group.  "We are proud to welcome RestorGenex to the OTCQX family and look forward to supporting the company in its continued growth."

"We are happy to upgrade to the OTCQX market and the wider exposure and increased liquidity this may bring," said Stephen M. Simes, CEO of RestorGenex.

Oppenheimer Wolff & Donnelly LLP serves as RestorGenex's Designated Advisor for Disclosure ("DAD") on OTCQX, responsible for providing professional guidance on OTCQX requirements and U.S. securities laws.

RestorGenex is a specialty biopharmaceutical company focused on developing a portfolio of first-in-class therapeutic products to treat diseases across the oncologic, ophthalmologic and dermatologic space.  RestorGenex's lead product is a novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in pre-clinical development for glioblastoma multiforme.  The current pipeline also includes a "soft" anti-androgen compound for the treatment of acne vulgaris.  RestorGenex's novel inhibition of the PI3K pathway and unique targeting of the androgen receptor show promise in a number of additional diseases, which the company is evaluating for the purpose of creating safe and effective treatments and innovative therapies.  For additional information, see: www.restorgenex.com.

About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates Open, Transparent and Connected financial marketplaces for 10,000 U.S. and global securities.  Through our OTC Link® ATS, we directly link a diverse network of broker-dealers that provide liquidity and execution services for a wide spectrum of securities.  We organize these securities into marketplaces to inform investors of opportunities and risks: the OTCQX® Best Marketplace; the OTCQB® Venture Marketplace; and the OTC Pink® Open Marketplace.  Our data-driven platform enables investors to easily trade through the broker of their choice at the best possible price and empowers a broad range of companies to improve the quality and availability of information for their investors.  To learn more about how we create better informed and more efficient financial marketplaces, visit www.otcmarkets.com.

OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and SEC regulated ATS.

Subscribe to the OTC Markets RSS Feed

Media Contact:
Saskia Sidenfaden, OTC Markets Group Inc., +1 (212) 896-4428, saskia@otcmarkets.com

SOURCE OTC Markets Group Inc.



RELATED LINKS

http://www.otcmarkets.com